Stocks of Gilead Sciences - Current price, Where to buy? Dividends
| Detail | Data |
|---|---|
| Stocks: | Gilead Sciences |
| ompany Name: | Gilead Sciences, Inc. |
| Ticker: | GILD |
| Exchange: | NasdaqGS |
| Outstanding stocks: | 1,246,969,984 |
| 24-hour Volume: | 7,734,770 |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Number of Employees: | 18000 |
| Country: | United States |
| City: | Foster City |
| Address: | 333 Lakeside Drive |
| P/E Ratio: | Forward P/E | EPS: | Forward EPS | Book value per share | Market capitalization |
|---|---|---|---|---|---|
| 16.22 | 9.83 | 4.5 USD | 7.43 USD | 18.33 USD | 81,464,737,792.00 USD |
| P/E Ratio: | 16.22 |
|---|---|
| Forward P/E: | 9.83 |
| EPS: | 4.5 USD |
| Forward EPS: | 7.43 |
| Book value per share: | 18.33 USD |
| Market capitalization: | 81,464,737,792.00 USD |
Gilead Sciences
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | 27,115,999,232.00 USD |
| Net Income: | 5,664,999,936.00 USD |
| Price-to-Book (P/B) Ratio: | 3.98 |
| PEG Ratio: | 1.99 |
Note: The data is approximate, subject to change over time, and may not be current; however, we strive for the highest possible accuracy.
Analysts' predictions
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation issued for Gilead Sciences stocks is: buy |
| Number of Analysts: | 25 |
| Highest Target Price: | 121 USD |
| Lowest Target Price: | 69 USD |
| Average Target Price: | 81 USD |
Note: The data is approximate. Recommendations and price forecasts for Gilead Sciences stocks based on analysts' ratings may change over time. Some recommendations may already be outdated and may not be accurate. We strongly advise against buying and selling stocks based on analysts' recommendations!
Dividend
| Dividends | Value |
|---|---|
| Dividend Amount | Company Gilead Sciences pays a dividend of 3.08 USD per share. |
| Annual Yield %: | 4.25 % |
| Ex-dividend Date: | 2024-03-14 |
| Average % Yield for 5 Years: | 3.97 % |
| Payout Ratio: | 66.67 % |
| Value of Last Dividend Paid: | 0.77 USD |
| Date of Last Dividend: | 2024-03-14 |
The dividend is displayed for the entire calendar year, however, it is usually paid out quarterly in parts. Data may change!
Where to Buy Gilead Sciences Stocks?
If you're interested in investing in Gilead Sciences stocks and believe in their future growth, you can purchase them through stock brokers like XTB or eToro. To make buying easier, we've prepared a table with offers from these brokers, including quick purchase of Gilead Sciences stocks through mobile apps with client support. In this table, you can compare brokers offering real Gilead Sciences stocks. Brokers providing the option to buy real stocks (not CFDs) are identified by "Real Stocks" in the comparison table column.
| Broker | Platforms | Regulation | Min. Deposit | Deposits / Withdrawals | CopyTrader | Real Stocks | Website Link |
|---|---|---|---|---|---|---|---|
 |
Proprietary platform, social network + CopyTrader™ | 100 USD | Bank transfer, credit cards, Skrill, PayPal, Neteller |
 Go to eToro
|
|||
 |
xStation, mobile version | 10 USD | Credit cards, Skrill, bank transfer |
 Go to XTB
|
|
|
| xStation, mobile version | Proprietary platform, social network + CopyTrader™ |
|
Go to XTB
|
Go to eToro
|
More Information about Gilead Sciences (GILD)
Gilead Sciences consistently proves itself as a leader in its industry. Total revenues for the last 12 months exceed 27,115,999,232.00 USD, demonstrating its strong market position and ability to generate high revenues. With EBITDA reaching 12,494,999,552.00 USD, Gilead Sciences maintains a high level of efficiency and profitability. This highlights its ability to manage operational costs effectively. A higher debt-to-equity ratio of 1.13 indicates higher leverage for Gilead Sciences compared to its equity, requiring cautious management. Gross margin of 77.80% shows that Gilead Sciences efficiently manages costs and maintains a high share of revenues. This is a sign of a strong market position. Profit margin of 20.89% underscores Gilead Sciences's efficiency in converting revenues into net income, which is crucial for its prosperity.
| Indicator | Value |
|---|---|
| Revenue, Debt, and Cash Flow | |
| Company Revenue: | 27,115,999,232.00 USD |
| EBITDA: | 12,494,999,552.00 USD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization. |
| Earnings Per Share: | 4.5 USD |
| Book Value Per Share: | 18.33 USD |
| Total Cash: | 8,350,000,128.00 USD |
| Total Cash per Share: | 6.70 USD |
| Total Debt: | 25,657,999,360.00 USD |
| Debt to Equity Ratio: | 1.13 |
| Quick Ratio: | 1.15 |
| Current Ratio: | 1.43 |
| Free Cash Flow: | 8,793,249,792.00 USD |
| Operating Cash Flow: | 8,006,000,128.00 USD |
| Company Margins | |
| Gross Margins: | 77.80 % |
| EBITDA Margins: | 46.08 % |
| Operating Margins: | 42.21 % |
| Profit Margins: | 20.89 % |
| Performance | |
| Return on Assets: | 9.8 % |
| Return on Equity: | 25.5 % |
| Earnings Growth (1 year): | -13.1% |
| Revenue Growth (1 year): | -3.7 % |
| Year-over-Year Quarterly Earnings Growth: | -12.9 % |
| Valuation | |
| Market Capitalization: | 81,464,737,792.00 USD |
| Enterprise Value: | 107,430,543,360.00 USD |
| EV/Revenue: | 3.962 |
| EV/EBITDA: | 8.598 |
| Number of Shares and Short Shares | |
| Float Shares: | 1,243,146,032 shares |
| Shares Outstanding: | 1,245,769,984 shares |
| Held Percent Insiders: | 0.00 % |
| Held Percent Institutions: | 88.53 % |
| Shares Short: | 19,674,265 |
| Shares Short Prior Month: | 15,662,309 |
| Date Short Interest: | 2024-02-29 |
| Shares Percent Shares Out: | 1.58 % |
| Short Ratio: | 2.55 |
| Beta: | 0.20 |
| Short Percent of Float: | 1.77 % |
| Předpokládaný počet akcií: | 1,245,769,984 |
Frequently Asked Questions (FAQ)
The company Gilead Sciences pays a dividend of 3.08 USD per share. At this rate, the annual yield is 4.25 %.
Gilead Sciences shares are traded on the stock exchange NasdaqGS under the ticker symbol: GILD. You can buy or trade them with a variety of stock brokers offering real stock trading services.
According to our data, there is a buy recommendation issued for Gilead Sciences shares by a total of 25 analysts. The average target price prediction is 81 USD per share.
The total number of Gilead Sciences shares on the exchange is 1,245,769,984.00, which, at the current market capitalization, values the company at 81,464,737,792.00 USD.
